1. Home
  2. RM vs IFRX Comparison

RM vs IFRX Comparison

Compare RM & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regional Management Corp.

RM

Regional Management Corp.

HOLD

Current Price

$41.65

Market Cap

334.1M

Sector

Finance

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.74

Market Cap

303.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RM
IFRX
Founded
1987
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
334.1M
303.4M
IPO Year
2011
2017

Fundamental Metrics

Financial Performance
Metric
RM
IFRX
Price
$41.65
$1.74
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$30.00
$6.25
AVG Volume (30 Days)
70.6K
1.3M
Earning Date
04-29-2026
05-07-2026
Dividend Yield
3.12%
N/A
EPS Growth
7.49
N/A
EPS
1.18
N/A
Revenue
$645,598,000.00
N/A
Revenue This Year
$12.94
N/A
Revenue Next Year
$8.97
N/A
P/E Ratio
$34.84
N/A
Revenue Growth
9.70
N/A
52 Week Low
$30.46
$0.74
52 Week High
$46.00
$2.95

Technical Indicators

Market Signals
Indicator
RM
IFRX
Relative Strength Index (RSI) 55.26 36.03
Support Level $35.76 $0.87
Resistance Level $44.30 $1.94
Average True Range (ATR) 1.60 0.15
MACD -0.28 -0.04
Stochastic Oscillator 45.33 3.97

Price Performance

Historical Comparison
RM
IFRX

About RM Regional Management Corp.

Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. The company is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: